Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy
- Tie Han†1,
- Yizhe Tang†1,
- Hideyo Ugai1,
- Leslie E Perry1,
- Gene P Siegal2, 4,
- Juan L Contreras3 and
- Hongju Wu1, 5, 6Email author
© Han et al; licensee BioMed Central Ltd. 2007
Received: 22 August 2007
Accepted: 24 October 2007
Published: 24 October 2007
Human adenovirus serotype 5 (Ad5) has been widely explored as a gene delivery vector for a variety of diseases. Many target cells, however, express low levels of Ad5 native receptor, the Coxsackie-Adenovirus Receptor (CAR), and thus are resistant to Ad5 infection. The Protein Transduction Domain of the HIV Tat protein, namely PTDtat, has been shown to mediate protein transduction in a wide range of cells. We hypothesize that re-targeting Ad5 vector via the PTDtat motif would improve the efficacy of Ad5-mediated gene delivery.
In this study, we genetically incorporated the PTDtat motif into the knob domain of Ad5 fiber, and rescued the resultant viral vector, Ad5.PTDtat. Our data showed the modification did not interfere with Ad5 binding to its native receptor CAR, suggesting Ad5 infection via the CAR pathway is retained. In addition, we found that Ad5.PTDtat exhibited enhanced gene transfer efficacy in all of the cell lines that we have tested, which included both low-CAR and high-CAR decorated cells. Competitive inhibition assays suggested the enhanced infectivity of Ad5.PTDtat was mediated by binding of the positively charged PTDtat peptide to the negatively charged epitopes on the cells' surface. Furthermore, we investigated in vivo gene delivery efficacy of Ad5.PTDtat using subcutaneous tumor models established with U118MG glioma cells, and found that Ad5.PTDtat exhibited enhanced gene transfer efficacy compared to unmodified Ad5 vector as analyzed by a non-invasive fluorescence imaging technique.
Genetic incorporation of the PTDtat motif into Ad5 fiber allowed Ad5 vectors to infect cells via an alternative PTDtat targeting motif while retaining the native CAR-mediated infection pathway. The enhanced infectivity was demonstrated in both cultured cells and in in vivo tumor models. Taken together, our study identifies a novel tropism expanded Ad5 vector that may be useful for clinical gene therapy applications.
Human adenovirus serotype 5 (Ad5) has been widely exploited as a gene delivery vector, owing largely to its superior gene delivery efficacy, minor pathological effect on humans, and easy manipulation in vitro. Several problems, however, have been identified in the course of development and application of Ad5-based gene therapy protocols, one of which is the inefficient gene delivery into target cells [1–3]. It is known that infection of Ad5 is initiated by attachment of its capsid fiber protein to the cell surface coxsackievirus adenovirus receptor (CAR), which is followed by interaction of its penton base with αv integrins that triggers the internalization of the viruses [4–7]. Many target cells, such as malignant tumor cells, are found to express very low level of CAR, and thus are resistant to Ad5 infection. Therefore, strategies to re-direct Ad5 infection via alternative receptors would be useful for gene therapy applications.
Since fiber, the capsid protein extruding from the Ad virion surface, is an essential mediator of Ad5 infection, fiber modification has been explored as a means to re-direct Ad5 tropism . Ad5 fiber is composed of an N-terminal tail that is attached to a penton base on the virion surface, a shaft domain consisting of 22 repeats of a 15-amino acid residue motif, and a C-terminal globular domain, named knob, which functions as a receptor binding domain. Because of the essential role of the fiber knob domain in mediating Ad5 infection, knob modification could be one of the most effective ways to re-direct Ad5 tropism. Indeed, both genetic and non-genetic strategies have been shown to successfully retarget Ad5 vectors. For example, bi-specific adapter proteins that bind both the knob domain and an alternative receptor expressed on the surface of the target cells have been employed to re-direct Ad5 infection [8–11]. In addition, genetic incorporation of RGD peptide and/or a polylysine epitope into the knob domain allowed Ad5 to infect cells through alternative receptors (cell surface integrins for RGD and negatively charged epitopes such as heparan sulfate proteoglycans for polylysine), thus greatly improving the gene delivery efficacy Ad5 vectors in many target cells [12–15].
Protein transduction domains (PTD) or Cell Penetrating Peptides (CPP) are a class of small peptides that can traverse the plasma membrane of many, if not all, mammalian cells [16–20]. Among these peptides, the PTD of the Tat protein (PTDtat) of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2) has been one of the most widely studied PTDs. PTDtat consists of 11 highly basic amino acid residues, YGRKKRRQRRR [21, 22]. The mechanism of how PTDtat crosses the cell membrane has been intensively studied, but controversies remain [23–26]. Nonetheless, it is commonly agreed upon that the interaction between the positive charge of the PTD domain and the negative epitopes, in particular, the heparan sulfate proteoglycans expressed on cell membranes, plays an essential role in the internalization of PTDtat fusion proteins [17, 20, 27]. Further studies suggest that the interaction between PTDtat and heparan sulfate is specified by both charge and structure of the peptide and the proteoglycans [17, 27–30].
Given the potential importance of the PTDs in drug delivery, much interest has been generated in exploiting this system as a tool to deliver therapeutic molecules or particles into mammalian cells. PTDs have already been widely used in the field of protein therapy whereby PTDs are fused to the protein of interest, and used to deliver the heterologous protein into cultured cells [17, 20, 31]. Interestingly, it has been demonstrated in several mouse studies that PTDtat fusion proteins can be delivered into different tissues in vivo following systemic administration, and therapeutic benefits have been observed [32–35]. In addition, PTDs have been used to deliver other large molecules or particles including plasmids, liposomes, nanoparticles, phages and viruses, with variable efficiency [36–41]. In these applications, PTDs were conjugated to the vehicle of interest by incubation in coupling solutions. In other words, the coating of the vehicle was not based on genetic modification, but on ionic or other interactions between the peptides and the vehicle.
Because of the potency of PTDtat in mediating cellular uptake of small and large molecules, in this study, we attempted to re-direct Ad5 infection via the PTDtat pathway. Previous studies have demonstrated pre-treatment of Ad particles with chemically synthesized PTDs or bi-specific adaptor proteins composed of the extracellular domain of CAR and PTDs improved Ad infection [37, 42]. Nonetheless, intrinsic to these non-genetic modification strategies, the efficiency of retargeting depended on the affinity and stability of protein-protein interactions, and thus may be highly variable in different systems. In addition, a large amount of peptide or adaptor protein is seen to be required for in vivo investigations. Our study was designed to retarget Ad5 vectors to the PTDtat pathway using a genetic capsid modification strategy. We genetically incorporated the sequences encoding the PTDtat peptide into the 3' end of the Ad5 fiber gene, rescued the modified viruses, and characterized them in detail. Our data demonstrated that genetic modification of Ad5 fiber with the PTDtat motif greatly improved the efficacy of gene delivery in both cultured cells and in tumor models. Our study thus identified a novel tropism expanded Ad5 vector that may be useful for clinical gene therapy applications, especially for applications involving gene delivery into low-CAR expressing cells.
Development of PTDtat-modified Ad5 vector – Ad5.PTDtat
CAR-binding activity of Ad5.PTDtat
Cell-binding activities of Ad5.PTDtat
Enhanced gene transfer efficacy of Ad5.PTDtat
Identification of pathways mediating Ad5.PTDtatinfection
In vivo gene transfer efficacy of Ad5.PTDtat
In this study, we sought to improve the gene transfer efficacy of Ad 5 vectors by genetic modification of the fiber knob domain with a PTDtat motif. Our data demonstrated the success of this strategy. The fiber modified Ad5 vector, Ad5.PTDtat, not only exhibited enhanced gene delivery efficiency of Ad5 vectors in low-CAR cells that are resistant to unmodified Ad5 infection, but also in high-CAR cells that are permissive to Ad5 infection. The enhanced infectivity of Ad5.PTDtat was found to be mediated by targeting of PTDtat to the negatively charged epitopes such as heparan sulfate containing proteoglycans on cell surface. In addition, we found PTDtat mediated Ad5.PTDtat infection is additive to native CAR-mediated infection as assessed by competitive inhibition assays, which was not unexpected since Ad5.PTDtat maintained full CAR-binding activity. More significantly, the enhanced gene delivery efficacy of Ad5.PTDtat was demonstrated in vivo using low-CAR U118MG tumor models, and employment of a recently developed non-invasive optical imaging system allowed us to visually detect the enhanced gene delivery in vivo.
As a cell penetrating peptide, PTDtat is capable of traversing the plasma membrane of mammalian cells. Since the initial description that PTDtat is responsible for the ability of the HIV Tat protein to enter mammalian cells, PTDtat has attracted tremendous interest as a drug delivery vehicle [16–20]. Further interest has been stimulated by the observation that PTDs can facilitate systemic delivery of biologically active recombinant proteins in vivo [32–35, 37]. Since inefficient gene delivery into target cells has been one of the major limitations in Ad5-mediated gene therapy, in this study, we attempted to employ PTDtat peptide to facilitate Ad5 mediated gene delivery. Employment of PTDs to facilitate virus infection has been investigated previously, but only using non-genetic methods [37, 42]. In particular, chemically synthesized PTDs or bi-specific adaptor proteins consisting of PTDs and the extracelluar domain of CAR have been used to coat Ad vectors. These strategies too resulted in enhanced gene delivery [37, 42]. Compared to the non-genetic methods, our genetically PTDtat modified vector has major advantages for two major reasons: 1) genetic modification allows stable interaction between Ad5 and the PTDtat targeting epitope, thus reducing the volatility associated with the affinity and stability of protein-protein interactions in the presence of different environmental factors. This is critical especially for in vivo applications; and 2) genetic modification does not require production of peptides or fusion proteins other than the viral vector, while large amounts of high quality protein/peptide production is required for non-genetic strategies (in addition to high quality production of the viral vectors), which is especially important for in vivo studies.
One issue associated with PTDtat-mediated protein delivery is the inefficient release of PTDtat fusion proteins from the endosomal compartments [24, 45–48]. It has been demonstrated that a large proportion of the PTDtat fusion protein remains trapped in non-cytosolic compartments even though it is efficiently taken up by the cells. This apparently would compromise the therapeutic effect of the fusion protein. In our study, we examined the distribution of Ad5.PTDtat particles in cells at various time points (from 0.5 hour to 4 hours) following addition of the viruses to the cells by immunofluorescent staining, and found that the distribution of Ad5.PTDtat inside the cells was similar to that of unmodified Ad5 vectors (data not shown). This indicates endosomal trapping is not significant, if any present at all, with Ad5.PTDtat infection of cells. In addition, the enhanced gene delivery mediated by Ad5.PTDtat confirmed that the virions were able to efficiently escape the endosomal compartment.
The potential utility of the infectivity-enhanced Ad5.PTDtat vector in cancer gene therapy was initially investigated in this study using low-CAR expressing tumor models. Indeed, many tumor cells have been shown to express very low levels of CAR, which is partially responsible for the low efficacy of Ad5 mediated cancer gene therapy in in vivo studies, especially in clinical trials [1–3]. The ability of Ad5.PTDtat to improve the gene delivery efficacy is attributable to the PTDtat motif, which binds to the negatively charged motifs expressed on cell surface, in particular, heparan sulfate containing proteoglycans that are widely expressed in a variety of cells including tumor cells [49–51]. In addition to cancer gene therapy, Ad5.PTDtat may also be applied in other gene therapy applications where infectivity-enhancement is beneficial. Infectivity-enhanced vectors will not only allow efficient gene delivery into low-CAR target cells, but also allow use of a reduced amount of viral vectors, thus reducing vector-associated toxicity.
Previous studies have developed several other infectivity-enhanced vectors, which include Ad5 vectors modified with RGD, polylysine, or knobs from other Ad serotypes [13–15, 52]. Since each of the modified vectors uses a unique extra targeting motif, the enhanced gene delivery efficacy in a specific cell type depends on the expression of individual receptors on its cell surface. Similar to PTDtat, the polylysine epitope, which is composed of a stretch of lysine residues, is highly basic, and can utilize heparan sulfate as its receptor. Nonetheless, the interaction between PTDtat and heparan sulfate is not only based on ionic intereactions, but also on the specific structures of the peptide and the proteoglycans [27–29]. Therefore, the choice of an infectivity-enhanced vector needs to be determined for each specific application involving gene delivery enhancement.
Our data showed that a genetically modified Ad5 vector, Ad5.PTDtat, maintained the ability to interact with its native receptor CAR, and delivered transgenes into both high-CAR and low-CAR cells more efficiently than the unmodified Ad5 vector. Our data further showed Ad5.PTDtat infected cells via both CAR and PTDtat pathways. More significantly, Ad5.PTDtat exhibited enhanced gene delivery in vivo in a tumor model, and thus may be useful for gene therapy applications involving low gene delivery efficacy.
The human embryonic kidney 293 cells stably transformed with Ad-E1 DNA, human lung carcinoma A549 cells, human cervix adenocarcinoma Hela cells, human embryonic rhabdomyosarcoma RD cells, and human glioma D65MG and U118MG cells were all obtained from the American Type Culture Collection (ATCC, Manassas, VA). The 293 cells, A549 cells and U118MG cells were cultured in Dulbecco's modified Eagle's medium/Ham's F12 medium (DMEM/F12) containing 10% fetal bovine serum (FBS) and 2 mM L-glutamine. Hela cells were cultured cultured in minimum essential Eagle medium (MEM) containing 10% FBS and 2 mM L-glutamine. Both RD and D65MG cells were cultured in DMEM containing 10% FBS and 2 mM L-glutamine. All of the cells were maintained at 37°C in a 5% CO2 humidified incubator.
Generation of the Ad5.PTDtatvector
Genetic modification of the Ad5 vector with PTDtat was achieved using our previously established fiber modification system . In brief, the fiber shuttle vector containing a unique SnaBI restriction site immediately in front of the stop code of the fiber gene, named pNEB.PK.SnaBI, was used to generate a PTDtat modification. The sense and antisense oligonucleotides encoding the PTDtat motif, 5'-phos-ACT TTT TCA TAC ATT GCG CAA GAA GGC GGT GGA GGG TAT GGC AGG AAG AAG CGG AGA CAG CGA CGA AGA TAA TAA A-3' (sense) and 5'-phos-TTT ATT ATC TTC GTC GCT GTC TCC GCT TCT TCC TGC CAT ACC CTC CAC CGC CTT CTT GCG CAA TGT ATG AAA AAG T -3' (antisense), were annealed and cloned into the fiber shuttle vector pNEB.PK.SnaBI. This resulted in the fiber modified shuttle vector pNEB.PK.PTDtat. In order to incorporate the modified fiber into an Ad5 genome, pNEB.PK.PTDtat was linearized and recombined in Escherichia coli (E. coli) BJ5183 with a linearized Ad5 backbone plasamid pVK50 that contained the CMV promoter driven GFP reporter gene in its E1 region. After the positive recombinant plasmid, designated pAd5.PTDtat, was identified, stable and high quality plasmid was obtained from E. coli DH5α after re-transformation of the construct. The modification was confirmed by sequencing analysis.
The modified virus Ad5.PTDtat was rescued and purified as previously described . In brief, the pAd5.PTDtat plasmid was digested with PacI (to release the viral genome), purified, and transfected into 293 cells stably expressing the complementary E1 genes. After the virus plaques formed, they were amplified in 293 cells, and purified utilizing a standard CsCl gradient protocol. The viral particle (VP) titer was determined using a conversion factor of 1.1 × 1012 VPs/ml per absorbance unit at 260 nm.
The ELISA binding assay was performed essentially as described . In brief, 109 VPs of either Ad5 or Ad5.PTDtat in 100 μl of 100 mM carbonate buffer (pH 9.5) was immobilized in each well of a 96-well maxisorp plate (Nunc, Roskilde, Denmark) by overnight incubation at 4°C. Following extensive washes with Tris-buffered saline (TBS) containing 0.05% Tween 20 (TBS-Tween), and blocking with 2% bovine serum albumin (BSA) in TBS-Tween, the viruses were incubated with varying amounts of purified recombinant sCAR. The binding of sCAR to the viruses was detected by incubation with anti-CAR antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA), followed by an AP-conjugated secondary antibody incubation. AP activity reflecting the amount of bound sCAR was determined using a color reaction with p-nitrophenyl phosphate (Sigma, St. Louis, MO) as recommended by the manufacturer. The absorbance at 405 nm (OD405) was obtained using PowerWaveHT 340 microplate reader (BioTek Instruments Inc., Winooski, VT).
Cell binding assay
Cells were cultured in 6-well plates until they were confluent. The plate was then cooled down on ice, and incubated with Ad5 or Ad5.PTDtat at an MOI of 5000 VPs/cell for one hour at 4°C. After washing cells twice with cold phosphate buffered saline (PBS) on ice, the cells were collected by incubation with Versene (0.53 mM EDTA). After two more washes with PBS, the cells were lysed and processed to isolate DNA (Qiagen Inc., Valencia, CA). The viral copy number in the DNA samples were obtained by quantitative PCR using primers designed for the E4 region of adenoviral genome. The data were normalized against actin DNA in each sample.
Gene transfer assay
Gene transfer efficacy of the viral vectors was assessed with the use of GFP reporter. In the assay, cells were plated in 24-well plates with a density of 105 cells per well the day before infection. Then the cells were infected with Ad5 or Ad5.PTDtat at MOIs of 100 or 500 VPs/cell as described previously . Two days later, GFP expression was examined by fluorescence microscopy and quantified by a Synergy HT fluorescence plate reader (BioTek Instruments Inc., Winooski, VT).
Competitive inhibition assays
Low-CAR U118MG cells or high-CAR A549 cells were plated in 24-well plates at a density of 105 cells per well the day before infection. Viruses equivalent to an MOI of 100 VPs/cell were used for each infection. To block cell surface CAR, recombinant knob protein was pre-incubated with cells at a final concentration of 50 μg/ml prior to viral infection , and to block the PTDtat epitope, the viruses were pre-incubated with 100 μg/ml of heparin [15, 54]. Two hours after infection, the cells were washed with PBS, and refreshed with complete media containing 10% FBS. The cells were cultured for two days in the humidified 37°C, 5% CO2 incubator, and GFP microscopy was performed to examine the transgene expression.
In vivogene delivery
The subcutaneous tumors were established in athymic nude mice using 1 × 107 U118MG cells per tumor per mouse. After the tumors developed to ~0.5 cm in diameter, PBS or 1010 VPs of Ad5 or Ad.PTDtat were injected into each tumor (n = 6). GFP expression was analyzed at 3, 7, and 10 days post infection using a custom-built non-invasive optical imaging system described previously . The mice were placed in the imaging chamber under anesthesia with 3% isoflurane. Green fluorescence images were acquired at f/8 with 20-second exposure using a combination of excitation filter HQ487/15× and emission filter D535/30m (Chroma Technology, Rockingham, VT) supported by WinView32 software (Roper Scientific Inc., Trenton, NJ). All of the procedures involving animals were approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham and performed according to their guidelines.
The authors thank Dr. Joel N. Glasgow for providing recombinant knob protein and Minghui Wang for assistance in quantitative PCR analysis. This work was supported by the NIH brain SPORE grant P50 CA097247 and the Juvenile Diabetes Research Foundation grants 1-2005-71 and 5-2007-660.
- Glasgow JN, Everts M, Curiel DT: Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther. 2006, 13 (9): 830-844. 10.1038/sj.cgt.7700928.PubMedPubMed CentralView ArticleGoogle Scholar
- Hedley SJ, Chen J, Mountz JD, Li J, Curiel DT, Korokhov N, Kovesdi I: Targeted and shielded adenovectors for cancer therapy. Cancer Immunol Immunother. 2006, 55 (11): 1412-1419. 10.1007/s00262-006-0158-2.PubMedView ArticleGoogle Scholar
- Rein DT, Breidenbach M, Curiel DT: Current developments in adenovirus-based cancer gene therapy. Future Oncol. 2006, 2 (1): 137-143. 10.2217/147966126.96.36.199.PubMedPubMed CentralView ArticleGoogle Scholar
- Bai M, Harfe B, Freimuth P: Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol. 1993, 67 (9): 5198-5205.PubMedPubMed CentralGoogle Scholar
- Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997, 275 (5304): 1320-1323. 10.1126/science.275.5304.1320.PubMedView ArticleGoogle Scholar
- Louis N, Fender P, Barge A, Kitts P, Chroboczek J: Cell-binding domain of adenovirus serotype 2 fiber. J Virol. 1994, 68 (6): 4104-4106.PubMedPubMed CentralGoogle Scholar
- Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993, 73 (2): 309-319. 10.1016/0092-8674(93)90231-E.PubMedView ArticleGoogle Scholar
- Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT: Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol. 2000, 74 (15): 6875-6884. 10.1128/JVI.74.15.6875-6884.2000.PubMedPubMed CentralView ArticleGoogle Scholar
- Li HJ, Everts M, Pereboeva L, Komarova S, Idan A, Curiel DT, Herschman HR: Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res. 2007, 67 (11): 5354-5361. 10.1158/0008-5472.CAN-06-4679.PubMedView ArticleGoogle Scholar
- Tang Y, Han T, Everts M, Zhu ZB, Gillespie GY, Curiel DT, Wu H: Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model. Gene Ther. 2007, 14 (6): 523-532. 10.1038/sj.gt.3302888.PubMedView ArticleGoogle Scholar
- Watkins SJ, Mesyanzhinov VV, Kurochkina LP, Hawkins RE: The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 1997, 4 (10): 1004-1012. 10.1038/sj.gt.3300511.PubMedView ArticleGoogle Scholar
- Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V: Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol. 2002, 76 (17): 8621-8631. 10.1128/JVI.76.17.8621-8631.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998, 72 (12): 9706-9713.PubMedPubMed CentralGoogle Scholar
- Wickham TJ, Roelvink PW, Brough DE, Kovesdi I: Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol. 1996, 14 (11): 1570-1573. 10.1038/nbt1196-1570.PubMedView ArticleGoogle Scholar
- Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, Han T, Curiel DT: Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther. 2002, 13 (13): 1647-1653. 10.1089/10430340260201734.PubMedView ArticleGoogle Scholar
- Deshayes S, Morris MC, Divita G, Heitz F: Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci. 2005, 62 (16): 1839-1849. 10.1007/s00018-005-5109-0.PubMedView ArticleGoogle Scholar
- Fittipaldi A, Giacca M: Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev. 2005, 57 (4): 597-608. 10.1016/j.addr.2004.10.011.PubMedView ArticleGoogle Scholar
- Joliot A, Prochiantz A: Transduction peptides: from technology to physiology. Nat Cell Biol. 2004, 6 (3): 189-196. 10.1038/ncb0304-189.PubMedView ArticleGoogle Scholar
- Snyder EL, Dowdy SF: Cell penetrating peptides in drug delivery. Pharm Res. 2004, 21 (3): 389-393. 10.1023/B:PHAM.0000019289.61978.f5.PubMedView ArticleGoogle Scholar
- Wadia JS, Dowdy SF: Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev. 2005, 57 (4): 579-596. 10.1016/j.addr.2004.10.005.PubMedView ArticleGoogle Scholar
- Ruben S, Perkins A, Purcell R, Joung K, Sia R, Burghoff R, Haseltine WA, Rosen CA: Structural and functional characterization of human immunodeficiency virus tat protein. J Virol. 1989, 63 (1): 1-8.PubMedPubMed CentralGoogle Scholar
- Vives E, Brodin P, Lebleu B: A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997, 272 (25): 16010-16017. 10.1074/jbc.272.25.16010.PubMedView ArticleGoogle Scholar
- Ferrari A, Pellegrini V, Arcangeli C, Fittipaldi A, Giacca M, Beltram F: Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol Ther. 2003, 8 (2): 284-294. 10.1016/S1525-0016(03)00122-9.PubMedView ArticleGoogle Scholar
- Fischer R, Kohler K, Fotin-Mleczek M, Brock R: A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J Biol Chem. 2004, 279 (13): 12625-12635. 10.1074/jbc.M311461200.PubMedView ArticleGoogle Scholar
- Fittipaldi A, Ferrari A, Zoppe M, Arcangeli C, Pellegrini V, Beltram F, Giacca M: Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem. 2003, 278 (36): 34141-34149. 10.1074/jbc.M303045200.PubMedView ArticleGoogle Scholar
- Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B: Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem. 2003, 278 (1): 585-590. 10.1074/jbc.M209548200.PubMedView ArticleGoogle Scholar
- Tyagi M, Rusnati M, Presta M, Giacca M: Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem. 2001, 276 (5): 3254-3261. 10.1074/jbc.M006701200.PubMedView ArticleGoogle Scholar
- Maccarana M, Casu B, Lindahl U: Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem. 1993, 268 (32): 23898-23905.PubMedGoogle Scholar
- Rusnati M, Tulipano G, Spillmann D, Tanghetti E, Oreste P, Zoppetti G, Giacca M, Presta M: Multiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharides. J Biol Chem. 1999, 274 (40): 28198-28205. 10.1074/jbc.274.40.28198.PubMedView ArticleGoogle Scholar
- Spillmann D, Witt D, Lindahl U: Defining the interleukin-8-binding domain of heparan sulfate. J Biol Chem. 1998, 273 (25): 15487-15493. 10.1074/jbc.273.25.15487.PubMedView ArticleGoogle Scholar
- Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF: Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med. 1998, 4 (12): 1449-1452. 10.1038/4042.PubMedView ArticleGoogle Scholar
- Asoh S, Ohsawa I, Mori T, Katsura K, Hiraide T, Katayama Y, Kimura M, Ozaki D, Yamagata K, Ohta S: Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci U S A. 2002, 99 (26): 17107-17112. 10.1073/pnas.262460299.PubMedPubMed CentralView ArticleGoogle Scholar
- Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, Lu A, Ran R, Graham SH, Chen J: In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. J Neurosci. 2002, 22 (13): 5423-5431.PubMedGoogle Scholar
- Orii KO, Grubb JH, Vogler C, Levy B, Tan Y, Markova K, Davidson BL, Mao Q, Orii T, Kondo N, Sly WS: Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice. Mol Ther. 2005, 12 (2): 345-352. 10.1016/j.ymthe.2005.02.031.PubMedPubMed CentralView ArticleGoogle Scholar
- Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999, 285 (5433): 1569-1572. 10.1126/science.285.5433.1569.PubMedView ArticleGoogle Scholar
- Eguchi A, Akuta T, Okuyama H, Senda T, Yokoi H, Inokuchi H, Fujita S, Hayakawa T, Takeda K, Hasegawa M, Nakanishi M: Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J Biol Chem. 2001, 276 (28): 26204-26210. 10.1074/jbc.M010625200.PubMedView ArticleGoogle Scholar
- Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, Giordano FJ, Sessa WC: Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med. 2003, 9 (3): 357-362. 10.1038/nm835.PubMedView ArticleGoogle Scholar
- Ignatovich IA, Dizhe EB, Pavlotskaya AV, Akifiev BN, Burov SV, Orlov SV, Perevozchikov AP: Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J Biol Chem. 2003, 278 (43): 42625-42636. 10.1074/jbc.M301431200.PubMedView ArticleGoogle Scholar
- Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R: Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol. 2000, 18 (4): 410-414. 10.1038/74464.PubMedView ArticleGoogle Scholar
- Sandgren S, Cheng F, Belting M: Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans. J Biol Chem. 2002, 277 (41): 38877-38883. 10.1074/jbc.M205395200.PubMedView ArticleGoogle Scholar
- Torchilin VP, Rammohan R, Weissig V, Levchenko TS: TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A. 2001, 98 (15): 8786-8791. 10.1073/pnas.151247498.PubMedPubMed CentralView ArticleGoogle Scholar
- Kuhnel F, Schulte B, Wirth T, Woller N, Schafers S, Zender L, Manns M, Kubicka S: Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors. J Virol. 2004, 78 (24): 13743-13754. 10.1128/JVI.78.24.13743-13754.2004.PubMedPubMed CentralView ArticleGoogle Scholar
- Seki T, Dmitriev I, Suzuki K, Kashentseva E, Takayama K, Rots M, Uil T, Wu H, Wang M, Curiel DT: Fiber shaft extension in combination with HI loop ligands augments infectivity for CAR-negative tumor targets but does not enhance hepatotropism in vivo. Gene Ther. 2002, 9 (16): 1101-1108. 10.1038/sj.gt.3301815.PubMedView ArticleGoogle Scholar
- Van Houdt WJ, Wu H, Glasgow JN, Lamfers ML, Dirven CM, Gillespie GY, Curiel DT, Haviv YS: Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models. Neuro Oncol. 2007, 9 (3): 280-290. 10.1215/15228517-2007-017.PubMedPubMed CentralView ArticleGoogle Scholar
- Albarran B, To R, Stayton PS: A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells. Protein Eng Des Sel. 2005, 18 (3): 147-152. 10.1093/protein/gzi014.PubMedView ArticleGoogle Scholar
- Al-Taei S, Penning NA, Simpson JC, Futaki S, Takeuchi T, Nakase I, Jones AT: Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors. Bioconjug Chem. 2006, 17 (1): 90-100. 10.1021/bc050274h.PubMedView ArticleGoogle Scholar
- Loison F, Nizard P, Sourisseau T, Le Goff P, Debure L, Le Drean Y, Michel D: A ubiquitin-based assay for the cytosolic uptake of protein transduction domains. Mol Ther. 2005, 11 (2): 205-214. 10.1016/j.ymthe.2004.10.010.PubMedView ArticleGoogle Scholar
- Wadia JS, Stan RV, Dowdy SF: Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med. 2004, 10 (3): 310-315. 10.1038/nm996.PubMedView ArticleGoogle Scholar
- Blackhall FH, Merry CL, Davies EJ, Jayson GC: Heparan sulfate proteoglycans and cancer. Br J Cancer. 2001, 85 (8): 1094-1098. 10.1054/bjoc.2001.2054.PubMedPubMed CentralView ArticleGoogle Scholar
- Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, Jayson GC: Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res. 2004, 10 (15): 5178-5186. 10.1158/1078-0432.CCR-03-0103.PubMedView ArticleGoogle Scholar
- Steck PA, Moser RP, Bruner JM, Liang L, Freidman AN, Hwang TL, Yung WK: Altered expression and distribution of heparan sulfate proteoglycans in human gliomas. Cancer Res. 1989, 49 (8): 2096-2103.PubMedGoogle Scholar
- Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT: Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res. 2002, 8 (1): 275-280.PubMedGoogle Scholar
- Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, Curiel DT: Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol. 2002, 76 (24): 12775-12782. 10.1128/JVI.76.24.12775-12782.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Glasgow JN, Kremer EJ, Hemminki A, Siegal GP, Douglas JT, Curiel DT: An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology. 2004, 324 (1): 103-116. 10.1016/j.virol.2004.03.028.PubMedView ArticleGoogle Scholar
- Le LP, Le HN, Dmitriev IP, Davydova JG, Gavrikova T, Yamamoto S, Curiel DT, Yamamoto M: Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst. 2006, 98 (3): 203-214.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.